CNS Anticancer Drug Discovery and Development Conference White Paper

Victor A. Levin, Peter J. Tonge, James M. Gallo, Marc R. Birtwistle, Arvin C. Dar, Antonio Iavarone, Patrick J. Paddison, Timothy P. Heffron, William F. Elmquist, Jean E. Lachowicz, Ted W. Johnson, Forest M. White, Joohee Sul, Quentin R. Smith, Wang Shen, Jann N. Sarkaria, Ramakrishna Samala, Patrick Y. Wen, Donald A. Berry, Russell C. Petter

Research output: Contribution to journalReview articlepeer-review

24 Scopus citations


Following the first CNS Anticancer Drug Discovery and Development Conference, the speakers from the first 4 sessions and organizers of the conference created this White Paper hoping to stimulate more and better CNS anticancer drug discovery and development. The first part of the White Paper reviews, comments, and, in some cases, expands on the 4 session areas critical to new drug development: pharmacological challenges, recent drug approaches, drug targets and discovery, and clinical paths. Following this concise review of the science and clinical aspects of new CNS anticancer drug discovery and development, we discuss, under the rubric "Accelerating Drug Discovery and Development for Brain Tumors," further reasons why the pharmaceutical industry and academia have failed to develop new anticancer drugs for CNS malignancies and what it will take to change the current status quo and develop the drugs so desperately needed by our patients with malignant CNS tumors. While this White Paper is not a formal roadmap to that end, it should be an educational guide to clinicians and scientists to help move a stagnant field forward.

Original languageEnglish (US)
Pages (from-to)vi1-vi26
StatePublished - May 24 2015


  • brain metastasis
  • chemotherapy
  • glioma
  • medulloblastoma
  • pharmacokinetics
  • pharmacology

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology
  • Cancer Research


Dive into the research topics of 'CNS Anticancer Drug Discovery and Development Conference White Paper'. Together they form a unique fingerprint.

Cite this